Search global stocks & ETFs...Ctrl K
Learn Mode
Hims & Hers Health IncHIMS
$26.19
-$1.82 (-6.498%)
$25.87
-$0.32 (-1.220%)
HIMS
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
2.73
Average
Valuation Model
Key Score
4.00
Good
Management
4.00
Good
Growth
5.00
Very Good
Profitability
4.00
Good
Fin. Health
5.00
Very Good
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$26.19
Baseline
High
$36.75
▲
40.32%
Avg
$27.34
▲
4.40%
Low
$18.18
▼
-30.58%
Analyst Ratings based on 23 Analysts
Strong Buy
209%
Buy
835%
Hold
1357%
Sell
000%
Strong Sell
000%
Hims & Hers Health, Inc. operates a telehealth consultation platform. The company is headquartered in San Francisco, California and currently employs 2,442 full-time employees. The company went IPO on 2019-09-09. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. The company connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. The company also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.Read More
Stock News
View All Updates
News88%Bullish
Hims CMO Appointment Highlights Longevity Focus And Raises Valuation Questions
23hYahoo
10 Health Care Stocks Whale Activity In Today's Session
1dBenzinga
TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
1dYahoo
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat
1dYahoo
1 Growth Stock Set to Flourishand 2 We Ignore
1dYahoo
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
2dYahoo
Hims & Hers Stock Jumps: What's Happening Today?
2dBenzinga
HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides
2dYahoo
A Major Catalyst Is Emerging For REITs
2dSeekingAlpha
Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings
3dYahoo
Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story
3dYahoo
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
3dSeekingAlpha
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks
3dYahoo
Hinge Health: 85% Gross Margins Don't Lie, This Is A Potential Hidden Gem
3dSeekingAlpha
Hims & Hers Expands With Eucalyptus Acquisition
4dYahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Traders Assess AI Momentum
4dYahoo
2 Unprofitable Stocks with Competitive Advantages and 1 Facing Headwinds
4dYahoo
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth Prospects
4dYahoo
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform
4dYahoo
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
4dYahoo
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
4dYahoo
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany
4dYahoo
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market
4dYahoo
Hims & Hers Expands Integrated Health Access via Platform Expansion
1wYahoo
Hims And Hers Canadian GLP 1 Push Tests Broader Wellness Subscription Thesis
1wYahoo
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform
1wYahoo
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
1wYahoo
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?
1wYahoo
CVS Expands GLP-1 Options For Members, Including The Reintroduction Of Zepbound As A Covered Medication
1wBenzinga
Hims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million Buy
1wYahoo
Hims & Hers Gains 5% on Insider Buying
1wYahoo
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
1wYahoo
Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot
1wYahoo
Hims & Hers Shares Rally On Million-Dollar Insider Purchase
1wBenzinga
Hims & Hers Health Form4 Filing Shows David Wells Bought 48,400 Shares At An Average Price Of $24.23/Share
1wBenzinga
HIMS Stock Heads For Weekly Loss — But Ex-Netflix CFO Is Buying The Dip Despite BofA’s GLP-1 Warning
1wYahoo
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
1wYahoo
B of A Securities Maintains Neutral on Hims & Hers Health, Lowers Price Target to $25
1wBenzinga
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
1wYahoo
10 Health Care Stocks With Whale Alerts In Today's Session
1wBenzinga
How The Hims & Hers Health (HIMS) Story Is Shifting With GLP‑1 Hopes And Margin Questions
1wYahoo
Benzinga Bulls And Bears: Take-Two, AMC, Rivian — And Markets Up For Eighth Straight Week
2wBenzinga
Hims & Hers Deepens Personalized Care Through Platform Expansion
2wYahoo
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $23
2wBenzinga
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
2wYahoo
The Silver Lining of Last Week's Hims & Hers Earnings Miss
2wYahoo
Canadians can now get digital prescriptions for 'generic Ozempic'
2wYahoo
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
2wYahoo
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
2wYahoo
Hims & Hers Health Begins Generic Semaglutide Sales In Canada With Plans Starting From C$149 Per Month
2wBenzinga